Halozyme Therapeutics Income Statement (2010-2025) | HALO

Frequency:

Period:

1Y 3Y 5Y 7Y 10Y All

Values in:

Download Data

Income Statement	Mar2021	Jun2021	Sep2021	Dec2021	Mar2022	Jun2022	Sep2022	Dec2022	Mar2023	Jun2023	Sep2023	Dec2023	Mar2024	Jun2024	Sep2024	Dec2024	Mar2025	Jun2025	Sep2025	Dec2025
Revenue & cost
Revenue (Quarter)	89.02M	136.46M	115.83M	102.00M	117.28M	152.37M	208.98M	181.50M	162.14M	221.04M	216.03M	230.04M	195.88M	231.35M	290.08M	298.01M	264.86M	325.72M	354.26M	451.77M
Cost of Revenue (Quarter)	18.22M	23.02M	18.59M	21.59M	15.92M	33.94M	47.32M	42.12M	35.17M	50.07M	54.82M	52.30M	28.33M	39.61M	49.43M	42.05M	48.40M	46.36M	55.24M	78.77M
Gross Profit (Quarter)	70.80M	113.44M	97.24M	80.42M	101.36M	118.42M	161.66M	139.38M	126.97M	170.97M	161.21M	177.74M	167.55M	191.75M	240.66M	255.95M	216.46M	279.36M	299.02M	373.00M
Operating items
Amortization - Intangibles (Quarter)						11.40M	27.19M	4.55M	17.84M	17.84M	20.34M	17.76M	17.76M	17.76M	17.76M	17.76M	17.76M	17.76M	17.76M	23.38M
Research & Development (Quarter)	9.01M	8.07M	8.49M	10.11M	11.85M	15.48M	16.70M	22.57M	17.98M	19.73M	17.32M	21.34M	19.11M	21.04M	18.46M	20.44M	14.80M	17.54M	17.25M	31.90M
Selling, General & Administrative (Quarter)	11.06M	12.32M	13.17M	13.77M	13.83M	57.48M	34.47M	37.75M	37.36M	38.95M	35.27M	37.61M	35.13M	35.71M	41.24M	42.25M	42.36M	41.61M	46.09M	77.03M
Other Operating Expenses (Quarter)	18.22M	23.02M	18.59M	21.59M	15.92M	45.35M	74.51M	46.67M	53.01M	67.91M	75.16M	70.06M	46.09M	57.37M	67.19M	59.82M	66.17M	64.12M	73.00M	435.73M
Operating Expenses (Quarter)	38.29M	43.41M	40.24M	45.47M	41.61M	118.31M	125.68M	106.99M	108.34M	126.58M	127.75M	129.00M	100.34M	114.12M	126.89M	122.51M	123.33M	123.28M	136.34M	544.66M
Operating Income (Quarter)	50.73M	93.05M	75.59M	56.53M	75.67M	34.06M	83.29M	74.51M	53.80M	94.46M	88.28M	101.03M	95.54M	117.23M	163.20M	175.50M	141.53M	202.44M	217.92M	-92.89M
EBIT (Quarter)	50.73M	93.05M	75.59M	56.53M	75.67M	34.06M	83.29M	74.51M	53.80M	94.46M	88.28M	101.03M	95.54M	117.23M	163.20M	175.50M	141.53M	202.44M	217.92M	-92.89M
Non-operating items
Other Non Operating Income (Quarter)	0.28M	0.22M	0.27M	0.33M	0.50M	-0.94M	0.64M	0.85M	2.98M	3.19M	4.79M	5.36M	4.99M	5.03M	6.47M	7.25M	6.82M	6.89M	5.33M	2.43M
Non Operating Income (Quarter)	0.28M	0.22M	0.27M	0.33M	0.50M	-0.94M	0.64M	0.85M	2.98M	3.19M	4.79M	5.36M	4.99M	5.03M	6.47M	7.25M	6.82M	6.89M	5.33M	2.43M
Net income details
EBT (Quarter)	28.09M	91.52M	74.11M	54.81M	74.41M	30.01M	73.71M	70.79M	52.24M	93.16M	101.76M	101.17M	96.03M	117.74M	165.15M	178.21M	143.83M	204.94M	218.96M	-100.85M
Tax Provisions (Quarter)	0.19M	0.06M	-142.48M	-11.96M	14.30M	7.33M	12.07M	13.09M	12.62M	18.40M	19.92M	15.79M	19.20M	24.50M	28.14M	41.20M	25.70M	39.78M	43.70M	40.74M
Profit After Tax (Quarter)	27.89M	91.46M	216.59M	66.77M	60.11M	22.68M	61.63M	57.70M	39.62M	74.75M	81.84M	85.39M	76.82M	93.25M	137.01M	137.01M	118.09M	165.16M	175.22M	-141.59M
Income from Continuing Operations (Quarter)	27.89M	91.46M	216.59M	66.77M	60.11M	22.68M	61.63M	57.70M	39.62M	74.75M	81.84M	85.39M	76.82M	93.25M	137.01M	137.01M	118.13M	165.16M	175.26M	-141.59M
Consolidated Net Income (Quarter)	27.89M	91.46M	216.59M	66.77M	60.11M	22.68M	61.63M	57.70M	39.62M	74.75M	81.84M	85.39M	76.82M	93.25M	137.01M	137.01M	118.13M	165.16M	175.26M	-141.59M
Income towards Parent Company (Quarter)	27.89M	91.46M	216.59M	66.77M	60.11M	22.68M	61.63M	57.70M	39.62M	74.75M	81.84M	85.39M	76.82M	93.25M	137.01M	137.01M	118.13M	165.16M	175.26M	-141.59M
Net Income towards Common Stockholders (Quarter)	27.89M	91.46M	216.59M	66.77M	60.11M	22.68M	61.63M	57.70M	39.62M	74.75M	81.84M	85.39M	76.82M	93.25M	137.01M	137.01M	118.13M	165.16M	175.26M	-141.59M
Additional items
EPS (Basic) (Quarter)	0.20	0.64	1.53	0.47	0.44	0.16	0.45	0.43	0.29	0.57	0.62	0.65	0.61	0.73	1.08	1.08	0.96	1.36	1.49	-1.16
EPS (Weighted Average and Diluted) (Quarter)	0.19	0.62	1.48	0.46	0.43	0.16	0.44	0.42	0.29	0.56	0.61	0.65	0.60	0.72	1.05	1.06	0.93	1.33	1.43	-1.12
Shares Outstanding (Weighted Average) (Quarter)	137.95M	142.49M	140.81M	140.65M	137.66M	137.80M	136.53M	136.84M	135.03M	133.37M	131.97M	131.93M	126.94M	127.12M	126.85M	126.83M	123.22M	121.34M	120.57M	119.84M
Shares Outstanding (Diluted Average) (Quarter)	148.54M	147.62M	146.69M	146.80M	141.28M	141.79M	141.02M	140.61M	137.90M	135.76M	135.23M	134.20M	128.89M	129.22M	130.13M	129.42M	126.64M	124.16M	122.33M	123.90M
EBITDA (Quarter)	50.73M	93.05M	75.59M	56.53M	75.67M	34.06M	83.29M	74.51M	53.80M	94.46M	88.28M	101.03M	95.54M	117.23M	163.20M	175.50M	141.53M	202.44M	217.92M	-92.89M
Interest Expenses (Quarter)	1.97M	1.75M	1.75M	2.06M	1.76M	3.10M	7.51M	4.57M	4.54M	4.49M	4.50M	5.22M	4.51M	4.52M	4.52M	4.54M	4.53M	4.39M	4.30M	4.91M
Tax Rate (Quarter)	0.68%	0.06%	-192.27%	-21.82%	19.22%	24.41%	16.38%	18.49%	24.16%	19.75%	19.58%	15.60%	20.00%	20.81%	17.04%	23.12%	17.87%	19.41%	19.96%	-40.40%

Research Tools

Halozyme Therapeutics Income Statement (2010-2025) | HALO

Create an account

Sign In

Reset Password